This site is intended for U.S. Healthcare Professionals only.

Phase 3 clinical data—
Ceftazidime-NS

Demonstrated clinical efficacy in a subset of patients with cIAI caused by ceftazidime-NS Gram-negative pathogens1

  • At baseline, 111 patients in the mMITT population had Gram-negative isolates that were not susceptible to ceftazidime, including 61 patients with E. coli and 26 patients with K. pneumoniae1
  • The clinical cure rate in this subset for AVYCAZ plus metronidazole was similar to the overall results1:
A chart of clinical cure rates in the Overall analysis population and Ceftazidime-NS Gram-negative pathogens

NS, nonsusceptible.

mMITT, microbiologically modified intent-to-treat.

TOC, test of cure.